Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02113553 | Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve | terminated | Phase 2 | 45 | Armando Santoro, MDOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02203513 | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer | terminated | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2022 |
| clinicaltrials |
| NCT04876378 | Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and Hand | terminated | — | 8 | University of California, San FranciscoOTHER | 1 | Sep 9, 2022 | clinicaltrials |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | terminated | Phase 1 | 21 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT03750240 | Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy | terminated | N/A | 2 | NYU Langone HealthOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT02457910 | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 30 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | terminated | Phase 1 / Phase 2 | 2 | Silverback TherapeuticsINDUSTRY | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04102618 | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer(AWARE-1) | terminated | Early Phase 1 | 26 | Oncolytics BiotechINDUSTRY | 1 | Aug 15, 2022 | clinicaltrials |
| NCT03674242 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2) | terminated | Phase 2 / Phase 3 | 27 | ERYtech PharmaINDUSTRY | 3 | Aug 1, 2022 | clinicaltrials |
| NCT03791736 | Evaluation of Impact of Sandostatin® Injection Before Axillary Clearance on Lymphocele Formation(SANDOSTATINE) | terminated | N/A | 4 | Institut Cancerologie de l'OuestOTHER | 0 | Jul 28, 2022 | clinicaltrials |
| NCT03147040 | AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer(GELATO) | terminated | Phase 2 | 23 | The Netherlands Cancer InstituteOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT02826512 | A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients | terminated | Phase 2 | 9 | The Netherlands Cancer InstituteOTHER | 1 | Jul 18, 2022 | clinicaltrials |
| NCT02340221 | A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy(SANDPIPER) | terminated | Phase 3 | 631 | Hoffmann-La RocheINDUSTRY | 28 | Jul 12, 2022 | clinicaltrials |
| NCT05063604 | Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer and Major Depression(CAMAD) | terminated | Phase 2 | 40 | Hospital Universitari de BellvitgeOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT04397029 | Assessing the Sensitivity of "SureTouch™" in Women Undergoing Diagnostic and Screening Mammography | terminated | N/A | 213 | George Washington UniversityOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT00754312 | A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer | terminated | Phase 1 | 1 | Syndax PharmaceuticalsINDUSTRY | 1 | Jun 6, 2022 | clinicaltrials |
| NCT02720185 | Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR | terminated | Phase 2 | 5 | University of Wisconsin, MadisonOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment | terminated | Phase 1 | 60 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 1, 2022 | clinicaltrials |
| NCT03874325 | Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer | terminated | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT00458796 | Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone | terminated | N/A | 1,500 | University of LeedsOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT02000596 | 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over. | terminated | Phase 2 | 2 | University of Maryland, BaltimoreOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT03787303 | Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma(B-TREUH) | terminated | Phase 2 | 7 | Aultman Health FoundationOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT01067144 | Stanford Accelerated Recovery Trial (START) | terminated | Phase 3 | 422 | Stanford UniversityOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT03448250 | Evaluating a Novel Web-based Intervention for Breast Cancer Survivors(OPTIMUNE) | terminated | N/A | 64 | Technical University of DortmundOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT01234532 | Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery(0927GCC) | terminated | Phase 2 | 5 | University of Maryland, BaltimoreOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT03630653 | Sentinel Lymph Node Procedure in Ipsilateral Invasive Breast Cancer Relapse(FIGARO) | terminated | N/A | 50 | Institut Cancerologie de l'OuestOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT03630809 | Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 | terminated | Phase 2 | 16 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT02482389 | Study of Preoperative Boost Radiotherapy | terminated | N/A | 3 | Duke UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT02269670 | Phase II Study of Everolimus Beyond Progression | terminated | Phase 2 | 3 | Emory UniversityOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT02824575 | Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer | terminated | Phase 1 | 28 | Montefiore Medical CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT02936947 | Study to Evaluate the Benefit of a High Frequency Ventilation System During Lung or Breast Cancer Radiotherapy Treatment | terminated | N/A | 8 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT02978716 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) | terminated | Phase 2 | 102 | G1 Therapeutics, Inc.INDUSTRY | 8 | Mar 23, 2022 | clinicaltrials |
| NCT04197999 | A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer | terminated | Phase 1 | 4 | GlycoMimetics IncorporatedINDUSTRY | 1 | Mar 22, 2022 | clinicaltrials |
| NCT02696759 | Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer | terminated | N/A | 15 | University of ArkansasOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT03733119 | ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 4 | University of Wisconsin, MadisonOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02704312 | Dosimetric Comparison of Doses in Both Positions (Prone and Decubitus) for Patient With Breast Cancer(PROCUBITUS) | terminated | N/A | 11 | University Hospital Center of MartiniqueOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT02994914 | GEriatric Determinants of Curative RAdiotherapy Scheme Choice for Breast Cancer ELderly Patient Treatment Compliance and Tolerance(GERABEL) | terminated | N/A | 241 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Feb 22, 2022 | clinicaltrials |
| NCT01036113 | A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer(PEG-SN38) | terminated | Phase 2 | 160 | Enzon Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT03619044 | The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.(REVER) | terminated | N/A | 4 | Institut Claudius RegaudOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT02236572 | Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score | terminated | Phase 2 | 17 | Yale UniversityOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT04367467 | Effect of PARP Inhibitors on Glomerular Filtration Rate | terminated | — | 2 | University of PennsylvaniaOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT00925652 | Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer(ABCDE) | terminated | Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT04296942 | BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) | terminated | Phase 1 | 1 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2022 | clinicaltrials |
| NCT02204462 | FBnTP Imaging of Breast Cancer | terminated | Phase 1 | 4 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT02541188 | Genotype and Phenotype in Early Onset Breast Cancer in Young Women on the Two Shores of the Mediterranean Sea(MediSein) | terminated | — | 460 | University Hospital, MontpellierOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT01755208 | Light-Scattering Spectroscopy for Detection of Breast Cancer | terminated | N/A | 110 | University of Southern CaliforniaOTHER | 1 | Nov 19, 2021 | clinicaltrials |
| NCT03057743 | Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer | terminated | — | 4 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT00816582 | PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer | terminated | N/A | 17 | British Columbia Cancer AgencyOTHER | 1 | Nov 16, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Sep 10, 2022source: clinicaltrials